{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:21Z","timestamp":1788459081537,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaip.2024.06.023","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:56:47Z","timestamp":1719284207000},"page":"2481-2489.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy"],"prefix":"10.1016","volume":"12","author":[{"given":"Marcus","family":"Shaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa M.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Hsu Blatman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.06.023_bib3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.06.023_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2024.06.023_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/03007995.2019.1660539","article-title":"Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States","volume":"36","author":"Sullivan","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2024.06.023_bib7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jaci.2007.07.055","article-title":"Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model","volume":"120","author":"Wu","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaip.2020.10.009","article-title":"Cost-effectiveness of biologics for allergic diseases","volume":"9","author":"Wu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3242","article-title":"Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis","volume":"2","author":"Shaker","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaip.2024.06.023_bib14","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1016\/j.jaip.2022.08.011","article-title":"The impact of allergy specialty care on health care utilization among peanut allergy children in the United States","volume":"10","author":"Greenhawt","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamapediatrics.2013.2376","article-title":"The economic impact of childhood food allergy in the United States","volume":"167","author":"Gupta","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaip.2024.06.023_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.anai.2020.01.004","article-title":"Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy","volume":"124","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib19","article-title":"Estimating cost-effectiveness of confirmatory oral food challenges in the diagnosis of children with food allergy","volume":"6","author":"Alsaggaf","year":"2019","journal-title":"Glob Pediatr Health"},{"key":"10.1016\/j.jaip.2024.06.023_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12064","article-title":"Incidence of anaphylaxis and accidental peanut exposure: a systematic review","volume":"11","author":"Muraro","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.06.023_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-045831","article-title":"Safely reducing hospitalizations for anaphylaxis in children through an evidence-based guideline","volume":"149","author":"Gaffney","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2024.06.023_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib24","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/cea.12211","article-title":"Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis","volume":"43","author":"Umasunthar","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2024.06.023_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaip.2017.05.006","article-title":"Quantitative assessment of the safety benefits associated with increasing clinical peanut thresholds through immunotherapy","volume":"6","author":"Baumert","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaci.2022.04.008","article-title":"The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study","volume":"150","author":"Peters","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2016.02.016","article-title":"The economic effect and outcome of delaying oral food challenges","volume":"116","author":"Couch","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4728","article-title":"Association of fatality risk with value-based drug pricing of epinephrine autoinjectors for children with peanut allergy: a cost-effectiveness analysis","volume":"1","author":"Shaker","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"21-5","key":"10.1016\/j.jaip.2024.06.023_bib29","first-page":"5.e1","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes","volume":"155","author":"Carroll","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2024.06.023_bib30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0140-6736(13)62301-6","article-title":"Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial","volume":"383","author":"Anagnostou","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.06.023_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18041","article-title":"Determining levers of cost-effectiveness for screening infants at high risk for peanut sensitization before early peanut introduction","volume":"2","author":"Greenhawt","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaip.2024.06.023_bib33","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.jaip.2021.02.058","article-title":"The cost-effectiveness of preschool peanut oral immunotherapy in the real-world setting","volume":"9","author":"Shaker","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib34","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jaip.2021.01.007","article-title":"A\u00a0cost-effectiveness analysis of epinephrine autoinjector risk stratification for patients with food allergy-one epinephrine autoinjector or two?","volume":"9","author":"Shaker","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2019.09.037","article-title":"Estimation of health and economic benefits of clinic versus home administration\u00a0of omalizumab and mepolizumab","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.06.023_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2018.06.018","article-title":"Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies","volume":"121","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.06.023_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2500\/aap.2019.40.4240","article-title":"Peanut allergy: burden of illness","volume":"40","author":"Shaker","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2024.06.023_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOP.0000000000000509","article-title":"An update on the impact of food allergy on anxiety and quality of life","volume":"29","author":"Shaker","year":"2017","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jaip.2024.06.023_bib39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/01.mlr.0000185750.18119.fd","article-title":"Functional impact and health utility of anxiety disorders in primary care outpatients","volume":"43","author":"Stein","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jaip.2024.06.023_bib40","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1016\/j.jaip.2020.07.035","article-title":"AAAAI Work Group Report: trends in oral food challenge practices among allergists in the United States","volume":"8","author":"Greiwe","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824006469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824006469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:28:48Z","timestamp":1730521728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824006469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2213219824006469"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.06.023","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}